GHRH and prostate carcinoma: Recently, many researchers are focusing on the development of GHRH (growth hormone releasing hormone—a hypothalamic polypeptide) antagonists as potential anti-cancer therapeutics since the GHRH is produced by various human tumors, including prostate cancer, and seems to exert an autocrine/paracrine stimulatory effect on tumors [139, 140].